Envafolimab

Envafolimab is an anti-PD-L1 nanobody used in cancer immunotherapy.^[1] It has been approved in China for the treatment of microsatellite instability-high (MSI-H) or MisMatch Repair deficient (dMMR) solid tumours.^[2] Envafolimab (KN035) has obtained the US FDA's orphan drug designation for advanced biliary tract cancer.

Envafolimab

Monoclonal antibody
Type	Single-chain variable fragment
Target	PD-L1
Clinical data
Drug class	Antineoplastic agent
ATC code	None
Identifiers
CAS Number	2102192-68-5
PubChem CID	381609252
DrugBank	DB15769
UNII	ES1M06M6QH